Free news subscriptions Free RSS feeds. Get the latest pharma news delivered to your inbox. A valid email address is required. Subscribe for free. The offer is subject to customary conditions as set forth in the Merger Agreement being filed today by the parties with the SEC. For further information please visit www. Human Genome Sciences -- exists to place new therapies into the hands of those battling serious disease.
Other trademarks referenced are the property of their respective owners. Investor Contact: Claudine Prowse, Ph.
Vice President, Investor Relations This communication contains forward-looking statements. But over the next decade, despite the funding from GSK and a series of large public stock offerings, HGS' own product development efforts foundered. Then, in , GSK became HGS' partner for Benlysta's development, remaining stalwart even after a failed Phase 2 trial a few months later threatened the compound's future and initiating the first of two dramatically successful Phase 3 studies in Nat.
You can also search for this author in PubMed Google Scholar. Reprints and Permissions. Ratner, M. Nat Biotechnol 30, Download citation. The tender offer and withdrawal rights are scheduled to expire at pm New York City time on Friday 29 June The closing of the tender offer is subject to the terms and conditions detailed in the offer document as filed on Schedule TO with the U.
Securities and Exchange Commission on 10 May and 23 May For further information please visit www.
0コメント